GSK Pharma Hits 3-Month High at Rs 2,640, Surges 32% in 7 Sessions

During intraday trading on Monday, GlaxoSmithKline Pharmaceuticals saw its share price shoot up by 5% to Rs 2,640 on the BSE, with a three-month high. The BSE Sensex dropped by 1% to 74,560 at 01:14 PM as GSK Pharma surged. In seven trading sessions, the stock of the company has been up by 32 percent on strong growth and sustained profitability for the quarter ended December 2024 (Q3FY25). This is the highest level of GSK Pharma shares since November 7, 2024.

GSK Pharma has announced a consolidated net profit of Rs 230 crore in Q3 FY25, compared to Rs 46 crore in the same quarter last year. The revenue grew by Rs 949.42 crore, or 17.9%, as compared to Rs 805.26 crore in the same quarter last year. The growth trajectory was mainly attributed to a strong volume performance in the general medicine segment and continued scale-up in vaccine offtake. The EBITDA margin has been reported to have increased by 270 basis points Y-o-Y to 29.7 percent, adjusted for one-off items, supported by lower employee costs but notwithstanding an upswing in other expenses.

Cruising some more, flagship brands in the company’s general medicines portfolio-such as Augmentin, Ceftum, and T-bact have enhanced their market position through higher market shares. The innovative respiratory portfolio, led by Nucala and Trelegy, is also growing, improving access to medicines across India. GSK has maintained its leading role in the market of private pediatric vaccines, while its adult vaccine sector, propelled by Shingrix (Herpes Zoster Vaccine), is resiliently grasping its breath.

In India, at the first half of FY26, GSK Pharma is slated to introduce two new assets in the gynaecological cancer segment (endometrial and ovarian cancers). Focus will also be placed on expanding adult immunization through education initiatives, and engaging healthcare practitioners.

As life expectancy rises and with an expanding elderly population, GSK Pharma envisages preventive healthcare via vaccination as a primary growth area. The adult vaccination initiatives focus on awareness programs as well as a robust marketing expected to drive future growth momentum are particularly in favor of the Shingrix vaccine.